SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has appointed Kaitlyn Arsenault, CPA, as Chief Financial Officer. Ms. Arsenault brings over 14 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology sectors.

See original here:
Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer